抗菌药物耐药监测在耐药控制中的作用与不足
本文为综述,讨论抗菌药物耐药监测应如何服务于治疗指南、抗菌药物目录、抗菌药物管理项目、公共卫生干预、感染控制政策及抗菌药物研发。文章指出欧洲虽由欧洲抗菌药物耐药监测网提供耐药菌年度报告,但各国监测仍碎片化且实验室数据存在结构性问题,多数数据无法与流行病学、临床或结局数据关联,遗传分型未常规开展,人源与动物监测协调不足,食品监测结果因商业敏感性鲜少公开。
要点
- 监测应覆盖治疗指南、处方集、抗菌药物管理、感染控制与药物研发等用途
- 仅基于临床样本的实验室监测难以作为新发病原体与耐药机制的早期预警系统
- 需加强各国监测系统建设并促进人源与兽医监测对接
核心结论
- 高质量、全面、实时的监测数据对降低抗菌药物耐药负担至关重要。
- 改进各国抗菌药物耐药监测系统并促进欧洲人源与兽医监测对接应成为科学与政治优先事项。
研究设计与样本
- 综述,未报告系统检索范围与研究样本量。
主要发现
- 欧洲抗菌药物耐药监测网提供耐药菌年度报告,但各国监测工作仍碎片化且异质,存在结构性问题和实验室数据问题。
- 多数发病率与患病率数据无法与相关流行病学、临床或结局数据关联。
- 未常规开展遗传分型以判断耐药趋势源于耐药菌株传播还是耐药决定因子在不同菌株与菌种间转移。
- 仅用临床样本的实验室监测不太可能作为新发病原体与耐药机制的早期预警系统。
- 人源抗菌药物耐药监测与动物监测协调不足,食品监测结果因被视为商业敏感而鲜少由监管者公开。
临床怎么用
- 监测数据应支持治疗指南、抗菌药物目录、抗菌药物管理项目、公共卫生干预与感染控制政策的评估。
- 应建设高质量、全面、实时的监测并加强人源与兽医监测衔接,以识别研究靶标微生物与人群。
局限性
- 不准确或不完整的监测数据会延误转化应对并妨碍识别研究靶标与重启休眠的药物发现项目。
- 各国监测碎片化、数据难以关联、遗传分型缺位及人畜监测协调不足限制了监测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions, infection control policies, and antimicrobial development. In Europe, although the European Antimicrobial Resistance Surveillance Network provides annual reports on monitored resistant bacteria, national surveillance efforts are still fragmented and heterogeneous, and have substantial structural problems and issues with laboratory data. Most incidence and prevalence data cannot be linked with relevant epidemiological, clinical, or outcome data. Genetic typing, to establish whether trends of antimicrobial resistance are caused by spread of resistant strains or by transfer of resistance determinants among different strains and species, is not routinely done. Furthermore, laboratory-based surveillance using only clinical samples is not likely to be useful as an early warning system for emerging pathogens and resistance mechanisms. Insufficient coordination of surveillance systems of human antimicrobial resistance with animal surveillance systems is even more concerning. Because results from food surveillance are considered commercially sensitive, they are rarely released publicly by regulators. Inaccurate or incomplete surveillance data delay a translational approach to the threat of antimicrobial resistance and inhibit the identification of relevant target microorganisms and populations for research and the revitalisation of dormant drug-discovery programmes. High-quality, comprehensive, and real-time surveillance data are essential to reduce the burden of antimicrobial resistance. Improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistance.
引用
- Tacconelli E, Sifakis F, Harbarth S, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2017. PMID: 29102325. doi:10.1016/S1473-3099(17)30485-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。